- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04041492
Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus
Effect of Supplementation With Vitamins D3 and K2 in Non-carboxyled Osteocalcine and Insulin Serum Levels in Patients With Diabetes Mellitus Type 2
Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life and increasing mortality. This could be related to changes in the serum levels of carboxylated Osteocalcin and Insulin, together with the deficit the daily consumption of vitamins D3 and K, which is crucial for the process of mineralization of the bone matrix.
Research question: What is the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus?
Hypothesis: Supplementation with Vitamins D3 and K2 modifies the serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus.
General Objectives: To assess the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated and Non-Carboxylated Osteocalcin in patients with Type 2 Diabetes mellitus.
Material and Methods: Clinical trial, double blind, randomization, 40 patients with DM2, 35-65 years, supplementation (3 months), clinical and laboratory determinations (uOC and Insulin).
- Group 1: Vitamin D3 1000UI + Placebo
- Group 2: Vitamin K2 100 mcg + Placebo
- Group 3 (Positive Control): Vitamins D3 1000UI + K2 100 mcg
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Type 2 diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia, being one of the main causes of mortality in our country.
There are different comorbidities, including bone demineralization, which involve an imbalance in the process of bone formation and resorption, which entails the risk of decreasing bone mineral density. These processes could be related to the serum levels of Non-carboxylated Osteocalcin and Insulin, said molecule locally modulates the process of bone mineralization.
On the other hand, it is known that the daily consumption of vitamins in a general diet in our population (specifically including vitamins D3 and K), is below the necessary basic requirements, so considering crucial elements for the benefit of Bone matrix mineralization, which is why the present study proposes supplementation with the aforementioned vitamins in patients with Type 2 DM, to avoid a decrease in bone mineral density, increasing the mortality rate of individuals suffering from it.
- The study subjects from the West of the country were invited to participate in the research protocol, where their objective was explained and the signing of the consent was requested under information, where a structured evaluation was subsequently carried out consisting of :
a) Comprehensive clinical evaluation (including general sociodemographic data of a complete medical history).
- Once the previous data was obtained, the randomization of the treatment was carried out, classifying the patients in the following groups:
- Group 1 Vitamin D3 1000UI + Placebo (Calcined Magnesia).
- Group 2 Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
- Group 3 (Positive Control) Vitamins D3 1000UI + K2 100 mcg.
- - Blood sample collection through Punzocat, which was placed in a red tube, for subsequent centrifugation at 3500rpm x 15 minutes, performing aliquots of the serum obtained and stored at -80 ° C and thus perform the pertinent quantifications of the molecules to study.
- Quantification of serum levels of non-carboxylated Osteocalcin and Insulin
a) The determinations corresponding to the serum levels of Non-carboxylated Osteocalcin and Insulin were made, both baseline prior to the intervention as well as the final quantification, once the supplementation was finished, by means of the indirect ELISA technique (commercial reagents -Takara were used - for the realization of these determinations), which involved the following process: In a plate the wells were coated with a first antibody, then a wash was performed to remove the excess antibody, after that, the sample in which the antigen was found was added, which was retained in the well after being recognized by the first antibody, a second wash was subsequently made to remove unbound material, then a solution with a second labeled anti-antigen antibody was applied. Thus each antigen molecule was bound to an antibody in the base that kept it fixed and a second antibody for its reaction and labeling. Finally, the plate was introduced into a spectophotometer and the absorbance was measured at a length of 450 nm, for both non-carboxylated Osteocalcin and Insulin.
- - The quantification in serum of cholesterol and triglycerides was carried out by using the fully automated random access analyzer equipment for clinical chemistry, model ERBA XL 200.
- - The evaluation of the HOMA index was calculated by using the equations HOMA-IR and HOMA-B, for insulin resistance (IR) and Percentage, respectively.
- - The daily of adherence to treatment was provided, so that they recorded all those important events that would ensure adequate intake of vitamins, as well as adverse reactions to them, which were evaluated in scheduled appointments, in addition to each The corresponding bottles were delivered consecutively for each of the 3 months of intervention, with the corresponding vitamins for each patient according to their allocation group.
- - Finally, in the last visit the results obtained during the whole study were made known to each of the patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44730
- Julio Iván Aguayo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Originating and residents of Western Mexico
- Both genres
- Age of 30-75 years
- Diagnosis of DM2 (ADA Criteria) of at least 5 years of evolution
- Sign an informed consent letter.
Exclusion Criteria:
- Use of active drugs for bone mineralization
- Pregnancy
- Lactation
- Creatinine or transaminase more than double the upper limit
- Diet added with calcium or vitamins (D, K).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Vitamin D3 1000UI + Placebo (Calcined Magnesia).
|
Supplementation at a dose of 1 capsule every 24 hours x 3 months
|
Experimental: Group 2
Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
|
Supplementation at a dose of 1 capsule every 24 hours x 3 months
|
Active Comparator: Group 3
Vitamin D3 1000UI + Vitamin K2 100 mcg
|
Supplementation at a dose of 1 capsule every 24 hours x 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-carboxylated osteocalcin
Time Frame: 3 months
|
Serum levels
|
3 months
|
Insulin
Time Frame: 3 months
|
Serum levels
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight
Time Frame: 3 months
|
kg
|
3 months
|
Height
Time Frame: 3 months
|
m
|
3 months
|
Body mass index
Time Frame: 3 months
|
Quetelet index
|
3 months
|
HOMA Index
Time Frame: 3 months
|
Insulin resistance
|
3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Hyperinsulinism
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Insulin Resistance
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- F-2017-1702-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
HighTide Biopharma Pty LtdRecruitingT2DM (Type 2 Diabetes Mellitus)China
-
AstraZenecaNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Supplementation with Vitamin D3 y K2
-
Hopital St. Georges, AjaltounOmicron Pharmaceuticals; Nattopharma ASAUnknownAortic Valve DiseaseLebanon
-
Medical University of BialystokLomza State University of Applied Sciences; International Science & Health... and other collaboratorsRecruitingVitamin D3 | Fracture Healing | Deficiency of Vitamin K2Poland
-
Institut de Recherche en Sciences de la Sante,...Active, not recruitingMalaria | Malnutrition, ChildBurkina Faso
-
Hospital Universitario Pedro ErnestoConselho Nacional de Desenvolvimento Científico e Tecnológico; Rio de Janeiro...RecruitingObesity | Vitamin D3 DeficiencyBrazil
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulTerminated
-
Karolinska InstitutetRegion Stockholm; Swedish Cystic Fibrosis AssociationUnknownCystic FibrosisSweden
-
Phoenix Children's HospitalCompletedMyelodysplastic Syndromes | Vitamin D Deficiency | Pediatric Cancer | Aplastic Anemia | Stem Cell Transplant Complications | Sickle Cell Anemia in Children | Thalassemia in Children | Blood Disorder | Pediatric Acute Myeloid Leukemia | Pediatric Acute Lymphoid LeukemiaUnited States
-
Columbia UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Rogier CaluweCompleted
-
Ankara City Hospital BilkentRecruitingPerineal InjuryTurkey